Literature DB >> 239698

Transamidase kinetics. Amide formation in the enzymic reactions of thiol esters with amines.

P Stenberg, C G Curtis, D Wing, Y S Tong, R B Credo, A Gray, L Lorand.   

Abstract

1. Beta-Phenylpropionylthiocholine and N-(5-aminopentyl)-5-dimethylaminonaphthalene-1-sulphonamide (dansylcadaverine) serve as a pair of water-soluble (pH7.5) model substrates for transamidating enzymes. Amide formation could be followed directly through fluorescence measurements by monitoring the continuous extraction of the water-soluble coupling product, N-(beta-phenylpropionyl)dansylcadaverine, into n-heptane. By this procedure, the steady-state kinetics of glutamine-lysine endo-gamma-glutamyltransferase from human plasma (fibrinoligase, thrombin- and Ca2+-activated blood coagulation Factor XII) and from guinea-pig liver (liver transglutaminase) were investigated at 25 degrees C. 2. With beta-phenylpropionylthiocholine as the varied substrate, Lineweaver-Burk plots with various concentrations of dansylcadaverine intercept on the horizontal axis, suggesting that formation of the acyl-enzyme is rate limiting. 3. On the basis of functional normality of active sites, kcat. values of 1.8 s(-1) and 0.9 s(-1) were obtained for the plasma and liver gamma-glutamyltransferase respectively. The two enzymes show identical affinities for the first substrate, beta-phenylpropionylthiocholine, with Ka 4 times 10(-4) M. 4. Utilization of the second substrate, dansylcadaverine, appears to be an order of magnitude more efficient with the liver enzyme. 5. N-(5-Amino-3-thiapentyl)-5-dimethylaminonaphthalene-1-sulphonamide (dansylthiacadaverine) could be used instead of dansylcadaverine in the fluorescent kinetic system. 6. Competitive inhibition by a non-fluorescent amine substrate histamine was also evaluated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 239698      PMCID: PMC1165385     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

Review 1.  Fibrinoligase: the fibrin-stabilizing factor system of blood plasma.

Authors:  L Lorand
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

2.  Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin.

Authors:  M L Schwartz; S V Pizzo; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1973-02-25       Impact factor: 5.157

3.  Titration of the acceptor cross-linking sites in fibrin.

Authors:  L Lorand; D Chenoweth; A Gray
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

4.  Structure and catalytic properties of hepatic transglutaminase.

Authors:  J E Folk
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

5.  Fibrin-stabilizing factor inhibitors. 11. Monodansylated weak aliphatic diamines.

Authors:  C Ljunggren; K J Hoffmann; P Stenberg; U Svensson; J L Nilsson; A Hartkoorn; R Lundén
Journal:  J Med Chem       Date:  1974-06       Impact factor: 7.446

6.  Kinetics of transamidating enzymes. Production of thiol in the reactions of thiol esters with fibrinoligase.

Authors:  C G Curtis; P Stenberg; K L Brown; A Baron; K Chen; A Gray; I Simpson; L Lorand
Journal:  Biochemistry       Date:  1974-07-30       Impact factor: 3.162

7.  Kinetic studies with transglutaminases. The human blood enzymes (activated coagulation factor 13 and the guinea pig hair follicle enzyme.

Authors:  S I Chung; J E Folk
Journal:  J Biol Chem       Date:  1972-05-10       Impact factor: 5.157

Review 8.  Site of synthesis of plasma and platelet factor XIII.

Authors:  J McDonagh; R H Wagner
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

9.  Mechanism of action of guinea pig liver transglutaminase. I. Purification and properties of the enzyme: identification of a functional cysteine essential for activity.

Authors:  J E Folk; P W Cole
Journal:  J Biol Chem       Date:  1966-12-10       Impact factor: 5.157

10.  Thiolester substrates for transamidating enzymes: studies on fibrinoligase.

Authors:  L Lorand; C H Chou; I Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

View more
  8 in total

1.  Reactivity of the N-terminal region of fibronectin protein to transglutaminase 2 and factor XIIIA.

Authors:  Brian R Hoffmann; Douglas S Annis; Deane F Mosher
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

2.  Synthesis and biological evaluation of omega-(N,N,N-trialkylammonium)alkyl esters and thioesters of carboxylic acid nonsteroidal antiinflammatory agents.

Authors:  M C Venuti; J M Young; P J Maloney; D Johnson; K McGreevy
Journal:  Pharm Res       Date:  1989-10       Impact factor: 4.200

3.  Evidence for filaggrin as a component of the cell envelope of the newborn rat.

Authors:  S Richards; I R Scott; C R Harding; J E Liddell; G M Powell; C G Curtis
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

Review 4.  Transglutaminases.

Authors:  L Lorand; S M Conrad
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

5.  Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity.

Authors:  S N Prasanna Murthy; Siiri Iismaa; Gillian Begg; Douglas M Freymann; Robert M Graham; Laszlo Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

6.  An equilibrium study of metal ion binding to human plasma coagulation factor XIII.

Authors:  B A Lewis; J M Freyssinet; J J Holbrook
Journal:  Biochem J       Date:  1978-02-01       Impact factor: 3.857

7.  Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases.

Authors:  Siiri E Iismaa; Sara Holman; Merridee A Wouters; Laszlo Lorand; Robert M Graham; Ahsan Husain
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

8.  Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention.

Authors:  William P Katt; Marc A Antonyak; Richard A Cerione
Journal:  Mol Pharm       Date:  2014-12-10       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.